JAGX news

Jaguar Health's board approved Series R convertible preferred stock. This corporate action prepares the company for potential equity financing, a strategic move often seen to bolster financial flexibility for development-stage businesses.

Jaguar Health, Inc. is converting a portion of its secured promissory note into shares of common stock without additional consideration. The exchange is structured to comply with Section 3(a)(9) of the Securities Act of 1933.

Jaguar Health, Inc. agreed to exchange a promissory note held by Streeterville Capital for unassigned common stock, effective September 23, 2026. This action is being taken with the intent to partition the debt in accordance with Section 3(a)(9) of the Securities Act.

Jaguar Health announced an agreement with Streeterville Capital to cancel a portion of its Secured Promissory Note in exchange for shares of common stock. This exchange is intended to reduce the company's outstanding debt obligations.

Jaguar Health issued a pre-funded common stock purchase warrant to secure financing for specified work, contingent upon a standalone registration statement within 45 days.

The company amended its certificate of incorporation to authorize an Eighth Reverse Stock Split, with the exact timing and ratio to be determined at a later date, which is expected to solely affect trading liquidity.

Napo Pharmaceuticals Inc., a wholly-owned subsidiary of Jaguar Health, entered into a Manufacturing and Supply Agreement with Alivus Life Sciences. This deal secures the supply of Crofelemer, the active ingredient in Mytesi, ensuring continued production capabilities for the company's flagship drug.

Jaguar's board initiated a process to review strategic alternatives including mergers, acquisitions, and partnerships to maximize shareholder value as it completes clinical work for a rare disease intestinal failure drug. The move comes as crofelemer shows promise in reducing parenteral support by u…

Jaguar Health and Uptown Capital amended their royalty interest agreement to set a monthly minimum payment floor of $750,000 beginning October 1, 2026. The amendment modifies payment obligations under the original $12 million royalty interest issued in December 2020.

Jaguar Health's board authorized the issuance of Series P non-convertible preferred stock with 300 shares designated. The filing establishes terms and conditions for this new preferred stock class, potentially indicating capital raising activity.

Jaguar Health announced approval of all five proposals submitted to stockholders at its May 22, 2026 Annual Meeting of Stockholders, which was adjourned until June 8, 2026. The company also announced CEO Lisa Conte will present virtually at the Emerging Growth Conference on June 10, 2026.

Jaguar Health is converting 3.72 shares of Series Q Preferred Stock into 31,958 shares of common stock held by Streeterville Capital under a May 26, 2026 agreement. The transaction represents a dilutive equity restructuring that simplifies the capital structure.

Jaguar Health received notice on May 26, 2026 that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), allowing its securities to remain listed and traded on Nasdaq. The compliance reinstatement follows a 816% net revenue increase in Q1 2026 versus Q1 2025, driven by a US out-license agr…

Jaguar Health agreed to exchange 4 shares of Series Q Perpetual Preferred Stock held by Streeterville Capital for 27,247 shares of common stock under Section 3(a)(9) of the Securities Act. The exchange represents a conversion of preferred equity into common stock with no additional consideration req…

Jaguar Health licensed U.S. commercial rights for Mytesi and Canalevia-CA1 to Future Pak for $16 million upfront plus $2 million contingent payment, driving Q1 2026 net revenue to approximately $19.3 million. The company is refocusing on crofelemer development for rare-disease intestinal failure ind…

Jaguar Health's board authorized a new series of preferred stock with 2,000 shares available for issuance in exchange for cash or other securities. The filing establishes the rights, preferences, and terms for Series Q Perpetual Preferred Stock but does not disclose pricing or immediate issuance det…